Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update

F Lorenzo; L Sirpa; BE Wahlin; N Marcel; JH Christensen; VS De; H Harald; KM Linton; A Aqeel; LW Wang; D Minh; E Brian; B David

Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update

F Lorenzo, L Sirpa, BE Wahlin, N Marcel, JH Christensen, VS De, H Harald, KM Linton, A Aqeel, LW Wang, D Minh, E Brian, B David

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S31-S31
Number of pages	1
Journal	American Journal of Hematology
Volume	97
Publication status	Published - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Lorenzo, F., Sirpa, L., Wahlin, BE., Marcel, N., Christensen, JH., De, VS., Harald, H., Linton, KM., Aqeel, A., Wang, LW., Minh, D., Brian, E., & David, B. (2022). Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update. American Journal of Hematology, 97, S31-S31.

@article{197c5b55b0224279827af3c938209888,

title = "Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update",

author = "F Lorenzo and L Sirpa and BE Wahlin and N Marcel and JH Christensen and VS De and H Harald and KM Linton and A Aqeel and LW Wang and D Minh and E Brian and B David",

year = "2022",

month = oct,

language = "English",

volume = "97",

pages = "S31--S31",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley & Sons Ltd",

}

Lorenzo, F, Sirpa, L, Wahlin, BE, Marcel, N, Christensen, JH, De, VS, Harald, H, Linton, KM, Aqeel, A, Wang, LW, Minh, D, Brian, E & David, B 2022, 'Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update', American Journal of Hematology, vol. 97, pp. S31-S31.

TY - JOUR

T1 - Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma

T2 - Phase 1/2 Trial Update

AU - Lorenzo, F

AU - Sirpa, L

AU - Wahlin, BE

AU - Marcel, N

AU - Christensen, JH

AU - De, VS

AU - Harald, H

AU - Linton, KM

AU - Aqeel, A

AU - Wang, LW

AU - Minh, D

AU - Brian, E

AU - David, B

PY - 2022/10

Y1 - 2022/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000866743000051&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0361-8609

VL - 97

SP - S31-S31

JO - American Journal of Hematology

JF - American Journal of Hematology

ER -

Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update

UN SDGs

Other files and links

Cite this